Treatment nonadherence is a recognized problem, but most practice settings use education alone to address it. Psychological counseling methods generate greater behavior change but are not widely used. Telehealth nursing can be used to integrate these methods into routine clinical practice. This study was a nonrandomized trial of a telehealth program that used motivational interviewing and cognitive— behavioral techniques to improve osteoporosis medication adherence. Registered nurses delivered the intervention to 402 participants recruited from provider offices across the United States. Initial participation rates were high in this community-based sample, although attrition also was high. Six-month adherence based on pharmacy and clinical interview data was significantly higher than the general population rate. A comparison with nonparticipants approached significance, and there was a significant dose—response effect. Most reasons given for nonadherence were psychological. The results support the use of psychological techniques to improve adherence and the use of telehealth to disseminate evidence-based patient counseling. (Am J Med Qual 2007;22 445-456)
Cummings N.Psychological approaches to disease management. Panel discussion at: Conference on Psychological Approaches to Disease Management; May 21, 2004; Reno, NV.
2.
Smith P., Andrews J.Drug compliance not so bad, knowledge not so good: the elderly after hospital discharge. Age Ageing. 1993;12:336-342.
3.
Cook PFPsychosocial interventions to improve medication compliance: a meta-analysis . http://www.scriptassistllc.com/vendor/research . Accessed June 8, 2006.
4.
McDonald HP, Garg AX, Haynes RBInterventions to enhance patient adherence to medication prescriptions. JAMA.2002; 288:2868-2879.
5.
Mullen PD, Green LW, Persinger GSClinical trials of patient education for chronic conditions: a comparative meta-analysis of intervention types. Prev Med.1985;14:753-781.
6.
Cook PFAdherence to medications. In: O'Donohue WT, Levensky ER, eds. Promoting Treatment Adherence: A Practical Handbook for Health Care Providers. Thousand Oaks, CA: Sage; 2006:183-202.
7.
Burke BL, Arkowitz H., Menchola M.The efficacy of motivational interviewing: a meta-analysis of controlled clinical trials. J Consult Clin Psychol.2003;71:843-861.
8.
Compas BE, Keefe FJ, Haaga Daf, Leitenberg H., Williams DASampling of empirically supported psychological treatments from health psychology: smoking, chronic pain, cancer and bulimia nervosa. J Consult Clin Psychol.1998;66:89-112.
9.
Rollnick S., Mason P., Butler C.Health Behavior Change: A Guide for Practitioners. New York, NY: Churchill Livingstone; 1999.
10.
Dolcini MM, Canin L., Gandelman A., Skolnik H.Theoretical domains: a heuristic for teaching behavioral theory in HIV/STD prevention courses. Health Promot Pract. 2004 ; 5:404-417.
11.
Prochaska JO , Prochaska JMWhy don't continents move? Why don't people change?J Psychother Integration. 1999; 9:102.
12.
Frosch DL, Kaplan RMShared decision making in clinical medicine: past research and future directions . Am J Prev Med.1999;17:285-294.
13.
Miller WR, Rollnick S.Motivational Interviewing. New York, NY: Guilford Press; 1992.
14.
Meichenbaum DC , Turk D.Facilitating Treatment Adherence: A Practitioner's Guidebook. New York, NY: Plenum Press; 1987.
15.
World Health Organization.Prevention and management of osteoporosis. http://whqlibdoc.who.int/trs/WHO_TRS_921.pdf . Accessed June 15, 2006.
16.
Alendronate (Fosamax) and risedronate(Actonel) revisited. Obstet Gynecol.2005;106:402-403.
17.
National Osteoporosis Foundation.Prevention: who's at risk?http://www.nof.org/prevention/risk.htm . Accessed August 24, 2007.
18.
Lippuner K. , von Overbeck J., Perrelet R., Bosshard H., Jaeger P.Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland. Osteoporos Int.1997;7:414-425.
19.
Ray NF, Chan JK, Thamer M., Melton LJ Iii.Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res.1997;12:24-35.
20.
Lippuner K. , Golder M., Greiner R.Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int.2004;16(suppl 2):S8-S17.
21.
National Committee for Quality Assurance.The State of Health Care Quality 2006. http://web.ncqa.org/tabid/447/Default.aspx . Accessed August 24, 2007.
22.
Centers for Medicare & Medicaid Services.Physician quality reporting initiative. http://www.cms.hhs.gov/PQRI/. Accessed March 7, 2007.
23.
Silverman SL , Watts NB, Delmas PD, Lange JL, Lindsay R.Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and aledronate (REAL) cohort study. Osteoporos Int.2007;18:25-34.
24.
National Council on Patient Information and Education.Prescription Medication Compliance: A Review of the Baseline of Knowledge. Washington, DC: National Council on Patient Information and Education; 1995.
25.
Miller PDOptimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther.2005;27:361-376.
26.
Chapman GBShort-term cost for long-term benefit: time preference and cancer control . Health Psychol.2005;24(suppl): S41-S48.
27.
Orbell S., Hagger M.Temporal framing and the decision to take part in Type 2 diabetes screening: effects of individual differences in consideration of future consequences on persuasion. Health Psychol.2006;25:537-548.
28.
Beck J.Improving medication compliance with cognitive techniques. Open Minds Advisor . 2000;August:1-3.
29.
Levy RAFailure to refill prescriptions: incidence, reasons and remedies. In: Cramer JA, Spilker B, eds. Patient Compliance in Medical Practice and Clinical Trials. New York, NY: Raven Press; 1991:11-18.
30.
National Osteoporosis Foundation.Physician's guide to prevention and treatment of osteoporosis. http://www.guideline.gov/summary/summary.aspx?doc_id=3862. Accessed August 15, 2006.
31.
Clemmesen B., Ravn P., Zegels B., Taquet AN, Christiansen C., Reginster JYA 2-year phase II study with 1 year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int.1997;7:488-495.
32.
Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA.1999;282:1344-1352.
33.
Lanza FL, Rack MF, Li Z., Krajewski SA, Blank MAPlacebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women. Aliment Pharmacol Ther.2002;14:1663-1670.
34.
McClung M., Geusens P., Miller P., et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med.2001;344:333-340.
35.
Mortensen L. , Charles P., Bekker PJ, Digennaro J., Johnston CC Jr.Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up . J Clin Endocrinol Metab.1998;83:396-402.
36.
Wysowski DK , Chang JTAlendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med.2005;165:364-365.
37.
Leite AF, Figueiredo PT, Melo NS, et al. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:14-21.
38.
Cargill JMMedication compliance in elderly people: influencing variables and interventions . J Adv Nurs.1992;17: 422-426.
39.
Amaral PLThe special case of compliance in the elderly. In: Gerber KE, Nehemkis AM, eds. Compliance: The Dilemma of the Chronically Ill. New York, NY: Springer; 1986:128-157.
40.
Salzman C.Medication compliance in the elderly. J Clin Psychol.1995;56(suppl 1):18-22.
41.
Book HESome psychodynamics of non-compliance. Can J Psychiatry. 1987;32:115-117.
42.
Luce MFDecision making as coping. Health Psychol.2005;24(suppl):S23-S28.
43.
Maisiak R., Austin J., Heck L.Health outcomes of two telephone interventions for patients with rheumatoid arthritis or osteoarthritis. Arthritis Rheum.1996;39:1391-1399.
Cook PFMethods for assessing medication compliance. http://www.scriptassistllc.com/vendor/research . Accessed June 8, 2006.
46.
Fletcher SW , Pappius EM, Harper SJMeasurement of medication compliance in a clinical setting: comparison of three methods in patients prescribed digoxin . Arch Intern Med.1979;139:635-638.
47.
Levine AJ, Hinkin CH, Marion S., et al. Adherence to anti-retroviral medications in HIV: differences in data collected via self-report and electronic monitoring. Health Psychol.2006;25:329-355.
48.
Anstrom KJ, Weinfurt KP, Allen ASEstimating causal effects in randomized studies with imperfect adherence: conceptual and statistical foundations. In: Bosworth HB, Oddone EZ, Weinberger M, eds. Patient Treatment Adherence: Concepts, Interventions, and Measurement. Mahwah, NJ: Erlbaum; 2006:453-474.
49.
McHugh MLCalculation and utility of a one-way chi-square in nursing practice. J SpecPediatr Nurs.2005;10:201-203.
50.
Little RJ, Yau Lhy.Statistical techniques for analyzing data from prevention trials: treatment of no-shows using Rubin's causal model. Psychol Methods. 1998;3:147-159.
51.
Ballinger M.Compliance dwindles as drug costs escalate. ManagedHealthc Exec. 2002;January:9-10.
52.
Kaiser Family Foundation.Survey finds four in 10 seniors do not take medications as prescribed. http://www.kff.org/medicare/med041905nr.cfm. Accessed August 28, 2006.
